Background and Aims: The breakthrough of PD-1/ PD-L1 blockage immunotherapy have brought huge benefit for many types of cancer patients especially those with PD-L1 highly expressed. However 60~70% of patients didn't response because of low or no PD-L1 expression. Find a solution to upregulate tumor PD-L1 expression is critical to increase overall response rate. We attempt to identify which kind of chemotherapeutic drugs could prime tumor PD-L1 expression and would provide a rationale for combination immunotherapy.
age immunotherapy have brought huge benefit for many types of cancer patients especially those with PD-L1 highly expressed. However 60~70% of patients didn't response because of low or no PD-L1 expression. Find a solution to upregulate tumor PD-L1 expression is critical to increase overall response rate. We attempt to identify which kind of chemotherapeutic drugs could prime tumor PD-L1 expression and would provide a rationale for combination immunotherapy.
Methods: We first focused on identifying whether the chemotherapeutic drugs used in first-line advanced Non-Small-Cell Lung Cancer (NSCLC) treatment has the ability to prime PD-L1 expression in NSCLC cell lines at their sub-lethal dosages by immunoblotting, RT-PCR, FACS analyses, and xenograft tumor assay. We then identify whether their PD-L1 priming ability could affect T cells functions by, in vitro T cells activation assay and T cell-mediated cytotoxicity assay. The syngeneic mouse tumor model used to confirm the effect of combined chemotherapeutic agents and anti-PD-L1 antibody approach.
Results:
The anti-metabolite chemotherapeutic agent (Pemetrexed, FU, and Gemcitabine), especially Pemetrexed showed a dose-dependent effect on PD-L1 priming. Tumor PD-L1 priming ability of these agents could further affect T cells activity and T cell-mediated cytotoxicity. Silencing of Thymidylate Synthase (TS), the target of Pemetrexed and 5-FU or Ribonucleotide Reductase Catalytic Subunit M1 (RRM1), the target of Gemcitabine, in cancer cells also showed PD-L1 priming effect and suppressed T cells activation. Interferon-gamma (IFN-g) mediated JAK1/2 signalling was not involved in the priming of anti-metabolites on PD-L1 expression. Finally, mouse syngeneic model confirmed the combination of Pemetrexed and PD-L1 antibody have a better therapeutic effect compared with anti-PD-L1 antibody alone or Pemetrexed alone.
Conclusion:
Our result provides a proof of concept on selecting antimetabolite chemotherapeutic agents for which had PD-L1 priming ability and could enhance the therapeutic effects by combining anti-PD1/PD-L1 antibodies therapy in NSCLC. Background and Aims: Lung cancer still becomes a worrying health issue, the major of death in malignant disease and the incidence rate may increase continuously. Most patients with lung cancer have been diagnosed with advanced stage lung cancer. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. To increase the cure rate and life expectancy, the lung cancer should be detected early when the cancer is still small and localized. Tumor antigen is tumor marker (biomarker) that provides information of growing cancer, which has been developed for early detection of lung cancer and therapy (immunotherapy) target. MAGE expression becomes sensitives marker in some type of cancer including lung cancer. Previous research stated that there is significant relationship between MAGE expression and histopathology of lung cancer and stage of lung cancer. The purpose of this research was to analyze the relationship between MAGE A3 expression and BAL specimen cytological result on NSCLC at Dr. Soetomo Regional Public Hospital of Surabaya Methods: A total of 14 patients with NSCLC who underwent bronchoscopy for the removal of BAL in pulmonary ward of Dr. Soetomo Regional Public Hospital that met the inclusion and exclusion criteria were included in this research, they were analyzed with fisher's exact test.
Results: There was only 1 (7,1%) subject with BAL cytological results of cancer cells (adenocarcinoma) of the 14 research subjects. Positive MAGE A3 expression only occurred in 4 subjects (28.6%) of 14 subjects who were diagnosed with NSCLC.
There was no significant relationship between MAGE A3 expression and histopathologic type. But, a promising result for improvement diagnosis lung cancer with biologic molecular technique. 
